^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Excerpt:
    ...Response duration, progression-free survival, and overall survival`Safety`Ability of various somatic activating mutations in the TK region of the epidermal growth factor receptor (EGFR) gene to predict response and toxicity`Molecular profile`Significance of germline polymorphisms of the EGFR gene, somatic amplification of the EGFR gene, and other molecular factors for their association with clinical outcome parameters...
    Trial ID:
    NCT00411047
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Nature
    Title:

    Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib

    Published date:
    11/20/2020
    Excerpt:
    This cohort study included 371 lung cancer patients....we found that the proportion of EGFR amplification in patients with drug resistance was higher than that in patients with drug sensitivity (40% vs 0%)....EGFR amplification was commonly detected in patients with acquired lcotinib/gefitinib resistance.
    DOI:
    10.1038/s41598-020-76791-y